AzTrials
AzTrials

Diabetes ComplicationsNCT05159856

Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes

An observational study of Diabetes Complications and type1diabetes, run by Steno Diabetes Center Copenhagen at 1 site in Denmark.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Aims: To investigate early markers of long-term diabetic complications and the association to an extended glucose metabolic profile comprising glucose control (current and past), glucose variability and insulin sensitivity in children and adolescents with type 1 diabetes (T1D). Read more about this study

Who is it for?
Ages 6 to 18 years
How many people
400 participants
Where
1 siteDenmark
Study dates
3 May 2022to Dec 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: 400 children or adolescents with type 1 diabetes for more than 12 months. Age between 6-18 years old.

Who may be able to join

  • T1D>12 months
  • 6-18 years old prior to inclusion
  • Followed at the Pediatric Diabetes outpatient clinic at Steno Diabetes Center Copenhagen
  • Speaks and reads Danish well enough to understanding the given oral and written information.
  • There is a written consent from the guardianship holder/holders for the child.

Who cannot join

  • T1D < 12 months
  • Known cardiovascular disease
  • Antihypertensive treatment

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Denmark1 site, 1 recruiting
  • Steno Diabetes Center Copenhagen

    Herlev, Herlev, 2730

    Julie A Damm, MD, +4527287020, julie.agner.damm.02@regionh.dk

    Jesper Johannesen, Dmsc, jesper.johannesen@regionh.dk

    Recruiting

Other trials in Denmark

About this study

Aims: To investigate early markers of long-term diabetic complications and the association to an extended glucose metabolic profile comprising glucose control (current and past), glucose variability and insulin sensitivity in children and adolescents with type 1 diabetes (T1D).

Background: Most Danish children and adolescents with T1D do not achieve their metabolic target and are at increased risk of developing long-term diabetic complications, reducing their life expectancy and increase their morbidity rate. Hence, improved metabolic control, a better understanding of what optimal metabolic control means, combined with detailed monitoring of the first markers of long-term complications and their reversibility or lack thereof are needed.

Read more

Methods: A prospectivel study of 400 children, aged 6-18 years old, with T1D>12 months. Early markers of long-term diabetic complications will be investigated as arterial stiffness, nerve dysfunction and nephropathy. Data on T1D onset, duration, treatment modality, self-monitoring-blood-glucose profiles, growth, weight, and pubertal status will be collected.

Blood sampling will include routine tests and markers of glucose, lipid, bone, and gastrointestinal metabolism. DXA-scan, Fibroscan, bone-age, eye-examination and physical activity will be measured. Data on retrospective glucose- and lipid-profiles will be collected. The children will be offered a followup every 5 years for the next two decades.

Perspectives: This study provides novel insight into the frequency of early markers of long-term diabetic complications and its association to the interplay of the pancreas, adipose, gastrointestinal and bone metabolic axis. Which can assist in identifying subgroups of children and adolescents requiring earlier in-depth screening for early markers of long-term diabetic complications, for putative interventions for prevention, hence reducing morbidity and mortality in T1D.

Read the detailed description

The project is designed as a cross-sectional cohort study. The study consists of a one-day visit where 400 children and adolescents with T1D will be thoroughly examined after an overnight fast.

The following examinations are parof this study:

  • Standard physical examination: Including cor/pulm/abdomen, heart rate and blood pressure measurement. Data regarding age, sex, diabetes duration, growth, weight, and pubertal status.

Blood sampling

  • Bloodsampling: Include routine tests (hemoglobin and iron metabolites, BS, HbA1c, electrolytes, creatinine, urea, LDL, HDL, triglyceride, total cholesterol), and markers of glucose (insulin, c-peptide), lipid (leptin, adiponectin), bone (VitD, calcium, PTH, phosphate, magnesium, BASP, OCN, P1NP, CTX, uOCN, sclerostine, RANKL, osteoprotegrin and osteoglycin), gastrointestinal (GLP-1, GIP and glucagon) metabolism. IGF-1, IGF-BP3, thyroid metabolism (TSH, T3, free T4), sex hormones, adrenal androgens, aldosterone. Thyroid and celiac disease autoantibodies. Markers for inflammation and endothelial dysfunction will be examined. Plasma, serum and urine will also be collected for a Biobank for future research e.g. for studying metabolomics.
  • Carotid-femoral pulse wave velocity: Assessed with the Sphygmocor (AtCor Medical) device to measure arterial stiffness in the large arteries.
  • Evaluation of the nervous system function:
  • Cardiac autonomic neuropathy function will be assessed by the Vagus device.
  • Large sensory nerve function test assessed by sural nerve conduction velocity and sural nerve amplitude, measured with the non-invasive handheld device DPNCheckTM (NeuroMetrix, Inc., Waltham, USA).
  • Small sympathetic nerve fiber function assessed by electrochemical skin conductance assessed using the non- invasive device Sudoscan™ (Impeto Medical, Paris, France).
  • Kidney: Three morning urine samples will be collected at home for analyses of albumin/creatinine ratio.
  • Bone age Measured on an x-ray of the left hand using BoneXpert software to adjust for potentially biological age.
  • Dual energy X-ray absorptiometry scan: Performed to evaluate body composition and bone mineral density.
  • Fibroscan: To determine the stiffness of the liver (liver elastography).
  • Eye-examination: Visus, OPTOS, OCT og OCTA.
  • Continuous blood glucose monitoring (CGM) Evaluation of glucose variability for at least 14 days. Most children and adolescent at our outpatient clinics use these as part of their regular regulation and treatment. If the participant normally uses a CGM-device, data on blood glucose variation from the past 90 days will be collected. If not a CGM-monitor will be placed on the upper arm and the participants will be instructed to wear it for the next 14 days.
  • AX3: Physical activity for 7 days will be measured. Questionnaire Physical activity, Life quality
  • Extended lungfunction

Medical history/journals Diabetes duration, treatment modality, insulin dosage, previous medication, episodes of diabetic ketoacidosis and hypoglycemia.

All earlier blood samples on: Hba1c, HDL, LDL, cholesterol. All earlier blood pressure, heart rate, weight, height, abdominal and hip circumference. Diabetic complication status: nephropathy, retinopathy, neuropathy or vascular complications. Data on current and prior asthma, atopy and eczema will be collected. Family history of type 2 diabetes, cardiovascular disease, asthma and atopy will be collected.

Insulin sensitivity Calculated using a validated score based upon Hba1c, waist circumference, fasting glucose and fasting insulin.

Participants will be recruited from the Paediatric Diabetes outpatient clinic at Steno Diabetes Center Copenhagen (SDCC) and Steno diabetes Center Sjælland (SDCS). All examinations and tests will be performed at SDCC. All children aged 6-18 years, with T1D for more than 12 months will be offered to participate. With a total of 950 T1D children/adolescent followed yearly at SDCC and 450 at SDCS the planned number of participants is realistic.

Sub-study I:

Insulin sensitivity (IS) has significant importance in T1D. The gold-standard measurement of IS is the hyperinsulinemic euglycemic clamp (HE clamp), a time-consuming procedure unfit for daily clinical practice. Thus, surrogate markers based on blood samples and anthropometric measurements have been developed. Only one of these surrogate markers is validated in youth with T1D and account for approximately 70 % of variance in IS. It has previously been demonstrated that lower IS, assessed by this surrogate marker, is associated with increased progression of arterial stiffness over time in youth with T1D. Arterial stiffness is associated with increased morbidity and mortality; thus, as IS is a modifiable risk factor it could serve as an instrument to reduce morbidity and mortality in T1D (17).

The hypothesis is that data from CGM devices can serve as a useful basis for constructing a surrogate marker for insulin sensitivity (IS), as CGM data provides comprehensive information on glucose metabolism and blood glucose patterns.

As a proof of concept, 14 pubertal boys (aged 14-18 years) will be invited to attend a second visit (Visit 1a), during which the gold-standard hyperinsulinemic-euglycemic (HE) clamp will be conducted. The clamp is performed in the morning after an overnight fast. A hyperinsulinemic state is induced through continuous insulin infusion for 2 hours and maintained until the end of the procedure.

Blood glucose is measured every 5-10 minute and glucose 20% is administrated based on these blood glucose measurements to keep a normal blood glucose level of 5-5.5 mmol/L. After approximately 2 hours, a steady state is achieved where the infusion of insulin and glucose balance one another. At this point glucose infusion rate (GIR) is measured and determines the glucose disposal rate (GDR). From the GDR the true physiological IS can be determined.

Data from CGM-devices and insulin administration 14 days prior to visit 1a will be analyzed in statistical models to predict IS, both direct measures (GDR) and assessed by the surrogate marker.

Statistics The methods applied to measure early markers of long-term diabetic complications both regarding arterial stiffness and the nerve system are all continuous parameters and no definitive cut offs between normal and early changes in children and adolescent are known. Therefore, sample size calculation for this study is not possible.

As described earlier, the SEARCH-study (7, 22) included some of the same outcome for evaluating cardiovascular-, nephrotic- and nerve system complications and showed statistically significant results with a number of 289 adolescents with T1D. The study plan to include 400 children and adolescent with T1D.

For descriptive data we will report frequency, mean (standard deviation) or median (interquartile range), as appropriate. Comparisons between relevant groups will be done for means with t-tests and medians with Mann-Whitney U-tests.

Linear regression models will be applied to assess the cross-sectional associations. Univariate and multivariable models will be used; adjustment will include risk factors and confounders based on prior evidence. In all analyses, model assumptions will be ascertained.

A two-sided p-value < 0.05 is considered statistically significant.

Keywords
pediatric, arteriel stiffness, pulse wave velosity, neuropathy, type 1 diabetes, early diabetic complications
Medical subject headings
Diabetes Complications, Diabetic Neuropathies, Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05159856
Study groupRoleWhat they receive
Prospective cohort study (observational)400 children/adolescents, aged 6-18 years, with type 1 diabetes for more than 12 months

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Arterial stiffness in children and adolescent with type 1 diabetes (T1D) > 12 months and its association to glycemic control (current and past).

    PWV is a measure of arterial stiffness (m/s) which can be done non invasively at bedside using a device called SphygmoCor CVMS machine (Atcor Medical, Sydney, Australia).

    Measured: 15.01.2022-15.02.2024

  2. Peripheral neuropathy assed by DPN-check in children and adolescent with type 1 diabetes (T1D) > 12 months

    Neuropathy assesed by DPN-check: Sural Nerve conduction velocity(m/s) of the Sural nerves by DPN-check.

    Measured: 15.01.2022-15.02.2024

  3. Autonom neuropathy assed by Sudoscan in children and adolescent with type 1 diabetes (T1D) > 12 months

    Neuropathy assesed by Sudoscan:

    Peripheral small-fiber sympathetic function (Sudoscan), measuring sudomotor function by electrochemical skin conductance (µS) in feet

    Measured: 15.01.2022-15.02.2024

  4. Prevalence of cardivascular autonomic neuropathy assed by VagusDevice in children and adolescent with type 1 diabetes (T1D) > 12 months

    The examination consists of 4 measures, all aimed at measuring heart rate. Measurements are taken for 5 minutes rest, change of position from lying to standing position, during deep breathing and by Valsalva (by breathing in a mouthpiece with a 40 mmHg resistance).

    Measured: 15.01.2022-15.02.2024

Secondary outcomes (2)
  1. The association between early markers of diabetic complications and glycemic control

    Hba1c (mmol/mol)

    Measured: 15.01.2022-15.02.2024

  2. The association between early markers of diabetic complications and glycemic control

    Continous glucose monitoring (time in range (70-180mg/dL))

    Measured: 15.01.2022-15.02.2024

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2021
  2. Study start3 May 2022
  3. Primary completionDec 2025 (estimated)
  4. Study completionDec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05159856
Sponsor's protocol ID
H-20038547
Status last verified
Nov 2024
First submitted
15 Nov 2021
Last updated
3 Jun 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes Complications and type1diabetes, run by Steno Diabetes Center Copenhagen at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Julie A Damm, MD (+4527287020, julie.agner.damm.02@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Arterial stiffness in children and adolescent with type 1 diabetes (T1D) > 12 months and its association to glycemic control (current and past). (time frame: 15.01.2022-15.02.2024). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in